Port K - Search Results

1

Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses.

Aregay A, Owusu Sekyere S, Deterding K, Port K, Dietz J, Berkowski C, Sarrazin C, Manns MP, Cornberg M, Wedemeyer H. Aregay A, et al. Among authors: port k. J Hepatol. 2019 Nov;71(5):889-899. doi: 10.1016/j.jhep.2019.06.025. Epub 2019 Jul 8. J Hepatol. 2019. PMID: 31295532

2

Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting.

Maasoumy B, Port K, Markova AA, Serrano BC, Rogalska-Taranta M, Sollik L, Mix C, Kirschner J, Manns MP, Wedemeyer H, Cornberg M. Maasoumy B, et al. Among authors: port k. PLoS One. 2013;8(2):e55285. doi: 10.1371/journal.pone.0055285. Epub 2013 Feb 1. PLoS One. 2013. PMID: 23383319 Free PMC article. Clinical Trial.

3

The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C.

Maasoumy B, Port K, Calle Serrano B, Markova AA, Sollik L, Manns MP, Cornberg M, Wedemeyer H. Maasoumy B, et al. Among authors: port k. Aliment Pharmacol Ther. 2013 Dec;38(11-12):1365-72. doi: 10.1111/apt.12523. Epub 2013 Oct 16. Aliment Pharmacol Ther. 2013. PMID: 24127648 Free article.

4

Compromised function of natural killer cells in acute and chronic viral hepatitis.

Lunemann S, Malone DF, Hengst J, Port K, Grabowski J, Deterding K, Markova A, Bremer B, Schlaphoff V, Cornberg M, Manns MP, Sandberg JK, Ljunggren HG, Björkström NK, Wedemeyer H. Lunemann S, et al. Among authors: port k. J Infect Dis. 2014 May 1;209(9):1362-73. doi: 10.1093/infdis/jit561. Epub 2013 Oct 23. J Infect Dis. 2014. PMID: 24154737

5

Effects of HDV infection and pegylated interferon α treatment on the natural killer cell compartment in chronically infected individuals.

Lunemann S, Malone DF, Grabowski J, Port K, Béziat V, Bremer B, Malmberg KJ, Manns MP, Sandberg JK, Cornberg M, Ljunggren HG, Wedemeyer H, Björkström NK. Lunemann S, et al. Among authors: port k. Gut. 2015 Mar;64(3):469-82. doi: 10.1136/gutjnl-2014-306767. Epub 2014 Apr 10. Gut. 2015. PMID: 24721903 Clinical Trial.

6

Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease.

Maasoumy B, Port K, Deterding K, Höner Zu Siederdissen C, Markova AA, Rogalska-Taranta M, Manns MP, Wedemeyer H, Cornberg M. Maasoumy B, et al. Among authors: port k. Eur J Gastroenterol Hepatol. 2014 Aug;26(8):836-45. doi: 10.1097/MEG.0000000000000121. Eur J Gastroenterol Hepatol. 2014. PMID: 24987822 Clinical Trial.

7

Anti-HDV IgM as a marker of disease activity in hepatitis delta.

Wranke A, Heidrich B, Ernst S, Calle Serrano B, Caruntu FA, Curescu MG, Yalcin K, Gürel S, Zeuzem S, Erhardt A, Lüth S, Papatheodoridis GV, Bremer B, Stift J, Grabowski J, Kirschner J, Port K, Cornberg M, Falk CS, Dienes HP, Hardtke S, Manns MP, Yurdaydin C, Wedemeyer H; HIDIT-2 Study Group. Wranke A, et al. Among authors: port k. PLoS One. 2014 Jul 29;9(7):e101002. doi: 10.1371/journal.pone.0101002. eCollection 2014. PLoS One. 2014. PMID: 25072849 Free PMC article.

8

Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting.

Höner Zu Siederdissen C, Maasoumy B, Deterding K, Port K, Sollik L, Mix C, Kirschner J, Cornberg J, Manns MP, Wedemeyer H, Cornberg M. Höner Zu Siederdissen C, et al. Among authors: port k. Liver Int. 2015 Jul;35(7):1845-52. doi: 10.1111/liv.12774. Epub 2015 Feb 2. Liver Int. 2015. PMID: 25556625

9

Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders.

Fülöp B, Biermer M, Cornberg M, Wedemeyer H, Port K, Heyne R, Zeuzem S, Peiffer KH, Welzel T, Herber A, Buggisch P, Moser C, Stoll S, Alshuth U, Berg T. Fülöp B, et al. Among authors: port k. Liver Int. 2015 Oct;35(10):2275-84. doi: 10.1111/liv.12832. Epub 2015 Apr 20. Liver Int. 2015. PMID: 25801095 Clinical Trial.

10

Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies.

Deterding K, Höner Zu Siederdissen C, Port K, Solbach P, Sollik L, Kirschner J, Mix C, Cornberg J, Worzala D, Mix H, Manns MP, Cornberg M, Wedemeyer H. Deterding K, et al. Among authors: port k. Aliment Pharmacol Ther. 2015 Oct;42(7):889-901. doi: 10.1111/apt.13343. Epub 2015 Aug 6. Aliment Pharmacol Ther. 2015. PMID: 26250762 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

55 results

Search Page

Filters